Today: 29 April 2026
Browse Category

NASDAQ:BSX 30 December 2025 - 10 February 2026

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific shares rose 0.7% to $74.61 by early afternoon Tuesday after a 2.8% drop Monday. New four-year Farapulse data showed higher treatment success than thermal ablation, with no long-term safety issues. Around 9.1 million shares traded by 1:15 p.m. The next major update is expected from the CHAMPION-AF trial results at ACC.26 on March 28.
10 February 2026
··
Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific shares slipped 0.2% to $77.49 in late-morning trading Friday, lagging a broader market rally. The stock remains under pressure after its electrophysiology segment missed sales estimates in the fourth quarter, triggering its steepest drop in over 25 years. Investors are watching for signs management can meet first-quarter growth targets. Trading volume stayed elevated as analysts revised forecasts.
6 February 2026
·
Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific shares rose 1.7% to $93.87 Friday afternoon, outpacing a broader market decline. The move comes ahead of the company’s Feb. 4 earnings report and conference call, its first since announcing a $14.5 billion deal to acquire Penumbra. Investors are watching for details on the acquisition’s impact and the 2026 outlook.
30 January 2026
···
Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific shares rose 1.7% to $94.12 Monday, outpacing medical-device peers and the S&P 500. Evercore reaffirmed its Outperform rating and $112 target, dismissing concerns about the $14.5 billion Penumbra acquisition. Investors await the Feb. 4 earnings call for updates on integration, financing, and demand trends. The Penumbra deal is expected to close in 2026.
26 January 2026
··

Stock Market Today

  • Ceres Power Surges Past Rolls-Royce, Nvidia, BP in FTSE 250 Rally
    April 29, 2026, 9:27 AM EDT. Ceres Power (LSE:CWR) leads the FTSE 250 stock gains in 2026 with a staggering 176% rise year-to-date, far outpacing Rolls-Royce, Nvidia and BP. The clean energy tech firm, specializing in licensing advanced solid oxide fuel cell and hydrogen technology, posted a remarkable 933% gain over the last year. Despite declining revenues - £32.6 million in 2025 down from £51.9 million the previous year - and no expected profits in 2026 or 2027, investor enthusiasm is fueled by the AI-driven data center boom. Its recent collaboration with Centrica aims to deploy efficient on-site power solutions swiftly for AI hubs and logistics centers. This positions Ceres as a crucial 'picks and shovels' provider amid the AI energy surge. However, over five years, the stock remains down 55%, prompting debate on its current valuation.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop